Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

40.86USD
19 Dec 2014
Price Change (% chg)

$2.24 (+5.80%)
Prev Close
$38.62
Open
$38.33
Day's High
$41.25
Day's Low
$37.85
Volume
715,556
Avg. Vol
280,177
52-wk High
$41.25
52-wk Low
$14.00

CMRX.OQ

Chart for CMRX.OQ

About

Chimerix, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have... (more)

Overall

Beta: --
Market Cap (Mil.): $1,618.13
Shares Outstanding (Mil.): 39.60
Dividend: --
Yield (%): --

Financials

  CMRX.OQ Industry Sector
P/E (TTM): -- 179.07 38.47
EPS (TTM): -1.56 -- --
ROI: -32.73 -0.72 18.25
ROE: -33.53 -1.88 19.13
Search Stocks

Chimerix antiviral to be tested in West African Ebola trial

- Chimerix Inc said its experimental broad-spectrum antiviral was one of two agents to be tested in a trial in confirmed Ebola patients in West Africa.

13 Nov 2014

Chimerix antiviral to be tested in West African Ebola trial

Nov 13 - Chimerix Inc said its experimental broad-spectrum antiviral was one of two agents to be tested in a trial in confirmed Ebola patients in West Africa.

13 Nov 2014

Chimerix drug used for Ebola shows promise in respiratory cases

- Chimerix Inc said its experimental oral antiviral, which was used earlier this week to treat the first Ebola patient diagnosed in the United States, improved the survival rate of patients with a certain type of respiratory infection.

08 Oct 2014

UPDATE 1-Chimerix drug used for Ebola shows promise in respiratory cases

Oct 8 - Chimerix Inc said its experimental oral antiviral, which was used earlier this week to treat the first Ebola patient diagnosed in the United States, improved the survival rate of patients with a certain type of respiratory infection.

08 Oct 2014

US STOCKS-Chimerix, Symantec rise in early trading

* Futures up: Dow 29 pts, S&P 5 pts, Nasdaq 7 pts (Adds Chimerix, Symantec)

08 Oct 2014

Chimerix antiviral drug shows potential in late-stage study

Oct 8 - Chimerix Inc said its experimental oral antiviral improved the survival rate of patients with a certain type of respiratory infection, according to preliminary data from a late-stage study.

08 Oct 2014

Nebraska hospital says treating its Ebola patient with Chimerix drug

- A Nebraska hospital treating U.S. patient Ashoka Mukpo for the deadly Ebola virus said on Tuesday it was using the experimental drug brincidofovir from Chimerix Inc.

07 Oct 2014

Nebraska hospital says treating its Ebola patient with Chimerix drug

Oct 7 - A Nebraska hospital treating U.S. patient Ashoka Mukpo for the deadly Ebola virus said on Tuesday it was using the experimental drug brincidofovir from Chimerix Inc .

07 Oct 2014

U.S. Ebola patient receives experimental drug from Chimerix

- After nearly a week in hospital, the first Ebola patient diagnosed in the United States began to receive an experimental therapy initially developed to treat other viral diseases, according to the Dallas hospital where he lies in critical condition.

06 Oct 2014

UPDATE 2-U.S. Ebola patient receives experimental drug from Chimerix

(Rewrites throughout with details on patient receiving drug and how it works)

06 Oct 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks